LT4982B - N-heterocikliniai dariniai kaip nos inhibitoriai - Google Patents

N-heterocikliniai dariniai kaip nos inhibitoriai Download PDF

Info

Publication number
LT4982B
LT4982B LT2002028A LT2002028A LT4982B LT 4982 B LT4982 B LT 4982B LT 2002028 A LT2002028 A LT 2002028A LT 2002028 A LT2002028 A LT 2002028A LT 4982 B LT4982 B LT 4982B
Authority
LT
Lithuania
Prior art keywords
amino
imidazol
methylpyrimidin
acetamide
ethyl
Prior art date
Application number
LT2002028A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2002028A (en
Inventor
Damian O. Arnaiz
John J. Baldwin
David D. Davey
James J. Devlin
Roland Ellwood Dolle Iii
Bin Ye
Gary B. Phillips
Gonghua Pan
John Parkinson
Kirk Mcmillan
Michael H.J. Ohlmeyer
Michael M. Morrissey
Shawn David Erickson
Vidyadhar Madhav Paradkar
Zuchun Zhao
Original Assignee
Berlex Laboratories,Inc.
Pharmacopeia,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlex Laboratories,Inc., Pharmacopeia,Inc. filed Critical Berlex Laboratories,Inc.
Publication of LT2002028A publication Critical patent/LT2002028A/xx
Publication of LT4982B publication Critical patent/LT4982B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LT2002028A 1999-08-26 2002-03-15 N-heterocikliniai dariniai kaip nos inhibitoriai LT4982B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/383,813 US6432947B1 (en) 1997-02-19 1999-08-26 N-heterocyclic derivatives as NOS inhibitors

Publications (2)

Publication Number Publication Date
LT2002028A LT2002028A (en) 2002-09-25
LT4982B true LT4982B (lt) 2003-01-27

Family

ID=23514822

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2002028A LT4982B (lt) 1999-08-26 2002-03-15 N-heterocikliniai dariniai kaip nos inhibitoriai

Country Status (34)

Country Link
US (11) US6432947B1 (sl)
EP (1) EP1206467B1 (sl)
JP (1) JP4739625B2 (sl)
KR (1) KR100708783B1 (sl)
CN (1) CN1206228C (sl)
AT (1) ATE256681T1 (sl)
AU (1) AU769405B2 (sl)
BG (1) BG65804B1 (sl)
BR (1) BR0014144A (sl)
CA (1) CA2376355C (sl)
CZ (1) CZ2002642A3 (sl)
DE (1) DE60007329T2 (sl)
DK (1) DK1206467T3 (sl)
EE (1) EE05199B1 (sl)
ES (1) ES2213599T3 (sl)
HK (1) HK1043594A1 (sl)
HR (1) HRP20020175B1 (sl)
HU (1) HUP0202450A3 (sl)
IL (2) IL148313A0 (sl)
LT (1) LT4982B (sl)
LV (1) LV12887B (sl)
MX (1) MXPA02002022A (sl)
NO (1) NO323886B1 (sl)
NZ (1) NZ517411A (sl)
PL (1) PL353539A1 (sl)
PT (1) PT1206467E (sl)
RO (1) RO122202B1 (sl)
RS (1) RS50378B (sl)
RU (1) RU2277094C2 (sl)
SI (1) SI20818B (sl)
SK (1) SK2622002A3 (sl)
UA (1) UA72930C2 (sl)
WO (1) WO2001014371A1 (sl)
ZA (1) ZA200201485B (sl)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
ATE250053T1 (de) * 1999-07-15 2003-10-15 Pharmacopeia Inc Bradikinin b1 rezeptor antagonisten
GB2361473C (en) * 2000-03-08 2005-06-28 Microgenics Corp Ecstasy-class analogs and use of same in detection of ecstasy-class compounds
MXPA02009755A (es) * 2000-04-03 2003-03-27 Bristol Myers Squibb Pharma Co Lactamas ciclicas como inhibidores de la produccion de proteina a-beta.
US20030055249A1 (en) * 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
US8386056B2 (en) * 2001-08-31 2013-02-26 Bio Control Medical (B.C.M.) Ltd. Parasympathetic stimulation for treating atrial arrhythmia and heart failure
US8571653B2 (en) * 2001-08-31 2013-10-29 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
US7885709B2 (en) * 2001-08-31 2011-02-08 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation for treating disorders
US7904176B2 (en) 2006-09-07 2011-03-08 Bio Control Medical (B.C.M.) Ltd. Techniques for reducing pain associated with nerve stimulation
EP1795192A3 (en) * 2002-04-30 2008-05-07 Bayer Schering Pharma Aktiengesellschaft 1-(Pyridazin-3-yl)-imidazole derivatives as inhibitors of nitric oxide synthase (NOS)
US6982259B2 (en) * 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
WO2004019986A1 (en) * 2002-08-29 2004-03-11 Schering Aktiengesellschaft Methods of treating acute respiratory distress syndrome
BR0314872A (pt) * 2002-10-18 2005-08-02 Pfizer Prod Inc Ligandos do receptor canabinóide e usos dos mesmos
JP2007522219A (ja) * 2004-02-12 2007-08-09 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性のアミノ複素環式調節物質
EP1568698A1 (en) * 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
MXPA06014247A (es) * 2004-06-10 2007-03-12 Irm Llc Compuestos y composiciones como inhibidores de la proteina quinasa.
KR100935273B1 (ko) * 2004-06-10 2010-01-06 아이알엠 엘엘씨 단백질 키나제 억제제 화합물 및 조성물
EP1805142A4 (en) * 2004-09-23 2009-06-10 Reddy Us Therapeutics Inc PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MX2007005857A (es) * 2004-11-17 2007-10-10 Mikana Therapeutics Inc Inhibidores de cinasa.
US20070123572A1 (en) * 2005-11-28 2007-05-31 Kalypsys, Inc. Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines
KR20070084574A (ko) * 2004-12-01 2007-08-24 칼립시스, 인코포레이티드 유도가능 산화질소 신타제 이량체화 억제제
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
BRPI0610514A2 (pt) * 2005-04-05 2016-11-16 Pharmacopeia Inc composto, composição farmacêutica, e, método de tratamento de um distúrbio
EP1923388A4 (en) 2005-08-12 2011-03-09 Takeda Pharmaceutical BRAIN / NEURONAL CELL PROTECTIVE AGENT AND THERAPEUTIC AGENT FOR SLEEP DISORDERS
BRPI0616630B8 (pt) * 2005-09-30 2021-05-25 Miikana Therapeutics Inc compostos de pirazol substituídos
WO2007062410A1 (en) * 2005-11-28 2007-05-31 Kalypsys, Inc. Imidazole derivatives as nitric oxide synthase dimerisation inhibitor
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US8017612B2 (en) * 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
WO2007125321A2 (en) * 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
JP2009534454A (ja) * 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
EP3146982B1 (en) 2006-10-03 2019-08-21 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200831104A (en) * 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200837064A (en) * 2006-10-04 2008-09-16 Pharmacopeia Inc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
EP1939181A1 (en) * 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
JP2010529193A (ja) * 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
EP2240021A4 (en) * 2008-01-30 2011-08-17 Glaxosmithkline Llc NEW SEH-HEMMER AND ITS USE
JP2011510998A (ja) * 2008-01-30 2011-04-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびその使用
WO2009097475A1 (en) * 2008-01-30 2009-08-06 Smithkline Beecham Corporation NOVEL sEH INHIBITORS AND THEIR USE
WO2009120094A2 (en) * 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
BR112012006130A2 (pt) 2009-09-18 2016-06-28 Volvo Lastvagnar Ab console para atamento para um chassi de veículo e veículo compreendendo um console de transporte de suspensão.
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
CN102617503B (zh) * 2011-03-03 2014-05-07 上海常丰生物医药科技有限公司 (s)-3-吗啉基羧酸的合成方法
ME03589B (me) 2011-04-01 2020-07-20 Astrazeneca Ab Terapeutski tretman
MX367640B (es) 2011-11-30 2019-08-29 Astrazeneca Ab Tratamiento combinado del cáncer.
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
EP3166938A4 (en) * 2014-07-11 2018-01-17 Northwestern University 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
GB201512635D0 (en) 2015-07-17 2015-08-26 Ucl Business Plc Uses of therapeutic compounds
DK3558997T3 (da) 2016-12-20 2021-04-19 Astrazeneca Ab Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
CN107115334A (zh) * 2017-03-04 2017-09-01 王宏 一种治疗免疫性流产的药物组合物
MX2020009950A (es) 2018-03-23 2021-04-28 Carmot Therapeutics Inc Moduladores de receptores acoplados a proteina g.
EP3628669A1 (en) 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
KR20240007251A (ko) 2021-05-13 2024-01-16 카모트 테라퓨틱스, 인크. G-단백질 결합 수용체의 조절제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339875A (ja) 1986-08-05 1988-02-20 Nissin Food Prod Co Ltd ピリミジン誘導体
DE4118720A1 (de) 1991-06-07 1992-12-10 Bayer Ag Substituierte imidazolinylpyrimidine
EP0548553A1 (en) * 1991-11-25 1993-06-30 Takeda Chemical Industries, Ltd. Optically active azole compounds, their production and use
AU665238B2 (en) * 1992-02-28 1995-12-21 Zenyaku Kogyo Kabushiki Kaisha S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
TW279864B (sl) * 1993-02-19 1996-07-01 Janssen Pharmaceutica Nv
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
EP0640599B1 (en) 1993-08-26 1998-03-04 Ono Pharmaceutical Co., Ltd. 4-Aminopyrimidine derivatives
US5426110A (en) 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
WO1996014842A1 (en) 1994-11-15 1996-05-23 Merck & Co., Inc. Substituted heterocycles as inhibitors of nitric oxide synthase
CN1066147C (zh) * 1995-11-01 2001-05-23 诺瓦提斯公司 嘌呤衍生物及其制备方法
ZA977427B (en) 1996-09-04 1998-03-02 Dainippon Pharmaceutical Co 2,4-disubstituted pyrimidine derivative, process for preparing the same, and a pharmaceutical composition containing the same.
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
CN1100777C (zh) * 1997-02-19 2003-02-05 伯莱克斯实验室公司 作为nos抑制剂的n－杂环衍生物
BR9815453A (pt) * 1997-03-11 2001-10-23 Du Pont Composto, composição herbicida e método para controle do crescimento de vegetação indesejada
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AOYAMA Y ET AL.: "Inhibition by a novel azole antifungal agent with a geranyl group on lanosterol 14 alpha-demethylase of yeast", BIOCHEM PHARMACOL., 1992, pages 1701 - 1705
CHABIN RM ET AL.: "Active-site structure analysis of recombinant human inducible nitric oxide synthase using imidazole", BIOCHEMISTRY, 1996, pages 9567 - 9575
CHWALISZ, K. ; BUHIMSCHI, I. ; GARFIELD, R. E: "Role of nitric oxide in obstetrics", PERINATAL AND NEONATAL MEDICINE, 1996, pages 292 - 329
D. CORY ADAMSON ET AL.: "Immunologic NO Synthase: Elevation in Severe AIDS Dementia and Induction by HIV-1 gp41", SCIENCE, 1996, pages 1917 - 1921
H. MICHAEL BELMONT MD ET AL.: "Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus", ARTHRITIS AND RHEUMATISM, 1997, pages 1810 - 1816
HUNOT S ET AL.: "Nitric oxide synthase and neuronal vulnerability in Parkinsons disease", NEUROSCIENCE. 1996 MAY;72(2):355-63. NITRIC OXI, 1996, pages 355 - 3563
J B WEINBERG ET AL.: "The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally admi", J. EXP. MED, 1994, pages 651 - 660
J. NEUROSCI: "Delayed Reduction of Ischemic Brain Injury and Neurological Deficits in Mice Lacking the Inducible Nitric Oxide Synthase Gene", J. NEUROSCI., 1997, pages 9157 - 9164, XP000867073
MAURICE M ET AL.: "Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture", FASEB J., 1992, pages 752 - 758, XP002715403
PARKINSON JF, MITROVIC B, MERRILL JE.: "The role of nitric oxide in multiple sclerosis", J MOL MED (BERL), 1997, pages 174 - 186
SMITH, M.A. ET AL.: "Widespread peroxynitrite-mediated damage in Alzheimers disease", J. NEUROSCI., 1997, pages 2653 - 2657, XP002379310
WALLACE MN: "Nitric oxide synthase in reactive astrocytes adjacent to beta-amyloid plaques", EXP NEUROL., 1997, pages 266 - 272

Also Published As

Publication number Publication date
US6864263B2 (en) 2005-03-08
PL353539A1 (en) 2003-12-01
NZ517411A (en) 2003-09-26
US20030078265A1 (en) 2003-04-24
US20020165203A1 (en) 2002-11-07
ZA200201485B (en) 2003-07-30
US20030027794A1 (en) 2003-02-06
RS50378B (sr) 2009-11-10
ES2213599T3 (es) 2004-09-01
DK1206467T3 (da) 2004-04-26
DE60007329T2 (de) 2004-06-09
EE05199B1 (et) 2009-08-17
EE200200091A (et) 2003-04-15
LT2002028A (en) 2002-09-25
US6841673B2 (en) 2005-01-11
NO323886B1 (no) 2007-07-16
KR20020062277A (ko) 2002-07-25
IL148313A0 (en) 2002-09-12
CA2376355C (en) 2009-10-27
HK1043594A1 (zh) 2002-09-20
US20030073669A1 (en) 2003-04-17
SK2622002A3 (en) 2002-09-10
DE60007329D1 (de) 2004-01-29
BG65804B1 (bg) 2009-12-31
JP2003507476A (ja) 2003-02-25
US20020183323A1 (en) 2002-12-05
SI20818A (sl) 2002-08-31
US6846829B2 (en) 2005-01-25
HUP0202450A2 (hu) 2002-11-28
MXPA02002022A (es) 2002-10-31
PT1206467E (pt) 2004-05-31
US6747031B2 (en) 2004-06-08
US6864368B2 (en) 2005-03-08
RU2277094C2 (ru) 2006-05-27
US20030060452A1 (en) 2003-03-27
KR100708783B1 (ko) 2007-04-19
US6432947B1 (en) 2002-08-13
US20030069210A1 (en) 2003-04-10
UA72930C2 (uk) 2005-05-16
NO20020925D0 (no) 2002-02-26
US6849739B2 (en) 2005-02-01
US20030004137A1 (en) 2003-01-02
SI20818B (sl) 2009-04-30
CA2376355A1 (en) 2001-03-01
LV12887B (en) 2003-01-20
US6887865B2 (en) 2005-05-03
ATE256681T1 (de) 2004-01-15
BR0014144A (pt) 2002-05-21
US20030083332A1 (en) 2003-05-01
HRP20020175B1 (hr) 2008-07-31
US20030092678A1 (en) 2003-05-15
US6670473B2 (en) 2003-12-30
EP1206467A1 (en) 2002-05-22
JP4739625B2 (ja) 2011-08-03
EP1206467B1 (en) 2003-12-17
US6841674B2 (en) 2005-01-11
HRP20020175A2 (en) 2005-10-31
AU7067100A (en) 2001-03-19
HK1051683A1 (en) 2003-08-15
YU12002A (sh) 2005-03-15
AU769405B2 (en) 2004-01-29
CZ2002642A3 (cs) 2002-08-14
BG106440A (en) 2002-11-29
CN1206228C (zh) 2005-06-15
IL148313A (en) 2008-04-13
CN1382136A (zh) 2002-11-27
NO20020925L (no) 2002-04-16
RO122202B1 (ro) 2009-02-27
WO2001014371A1 (en) 2001-03-01
HUP0202450A3 (en) 2003-12-29

Similar Documents

Publication Publication Date Title
RU2277094C2 (ru) Производные n-гетероциклических соединений, фармацевтическая композиция на их основе и способ лечения
ES2292488T3 (es) Derivados de la urea, como agentes antiinflamatorios.
DE69612949T2 (de) Neue benzimidazolderivate mit cgmp-phosphodiesterase inhibierender wirkung
AU2002340282B2 (en) Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
EA007062B1 (ru) Новые дигидроптеридиноны, способы их получения и их применение в качестве лекарственных средств
KR20090036573A (ko) 신규한 피리딘 유사체
CA2453147A1 (en) Methods of treating cytokine mediated diseases
EA021025B1 (ru) Соединения, эффективные в качестве ингибиторов ксантиноксидазы, способ их получения и содержащая их фармацевтическая композиция
KR20010080599A (ko) 아미노피라졸 유도체
PT1024138E (pt) Derivados de pirazole
KR20090031605A (ko) 신규한 피리딘 유사체
EP1567507B1 (en) 1,2,3- triazole amide derivatives as cytokine inhibitors
US3169966A (en) Aminopyrazoles
CA2504213A1 (en) New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
EA010392B1 (ru) Производные имидазолов, способ их получения и их применение в качестве лекарственного средства
BRPI1007902B1 (pt) Compostos de fenilmidazol
JPH10513172A (ja) ５−ｈｔ▲下１ｄ▼受容体アゴニストとしての置換１，４−ピペラジン−ヘテロアリール誘導体
JP2008501775A (ja) オキシトシン拮抗剤としての置換トリアゾール誘導体
BG100209A (bg) Пиролохинолинонови производни с позитивна инотропна и лузитропна активност
US5356922A (en) Imidazole compounds, processes for their preparation, pharmaceuticals based on these compounds and some intermediates
JPH0971564A (ja) ベンズアミドオキシム誘導体及びその医薬用途
JPH10130240A (ja) Ｉｃａｍ−１産生阻害剤
JPWO1994026737A1 (ja) イミダゾリルキノキサリンジオン誘導体及びその医薬組成物

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20100824